Alector Enters into a Licensing Agreement with Innovent Biologics to Develop and Commercialize AL008 in Oncology Indications in China
Alector, Inc. (ALEC)
Last alector, inc. earnings: 3/24 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
AL008 is Alector’s dual function SIRP-alpha inhibitor and Fc gamma receptor activator antibody targeting the innate immune system for oncology indicationsThe partnership with Innovent enables Alector to continue to expedite global development of it's immuno-oncology pipeline SOUTH SAN FRANCISCO, Calif., March 25, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company and leader in the discovery and development of therapeutics that harness the innate immune system, and Innovent Biologics, a leading Chinese biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, jointly announced today the execution of a regional licensing agreement to develop and commercialize AL008 for oncology indications in China. “Innovent is a leading biopharmaceutical company in China, and we have been impressed with the diligence and speed with which the Innovent tea
Show less
Read more
Impact Snapshot
Event Time:
ALEC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALEC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALEC alerts
High impacting Alector, Inc. news events
Weekly update
A roundup of the hottest topics
ALEC
News
- Alector, Inc. (NASDAQ: ALEC) had its price target lowered by analysts at HC Wainwright from $35.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
- ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study [Yahoo! Finance]Yahoo! Finance
- Alector, Inc. (NASDAQ: ALEC) had its price target lowered by analysts at BTIG Research from $16.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- Alector, Inc. (NASDAQ: ALEC) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Alector, Inc. (NASDAQ: ALEC) was downgraded by analysts at Morgan Stanley from an "equal weight" rating to an "underweight" rating. They now have a $3.00 price target on the stock, down previously from $10.00.MarketBeat
ALEC
Earnings
- 11/6/24 - Beat
ALEC
Sec Filings
- 11/29/24 - Form 144
- 11/29/24 - Form 144
- 11/29/24 - Form 144
- ALEC's page on the SEC website